In this study, we found that the frequency of Tregs such as CD4+CD25+ Treg, CD4+CD25+ Foxp3 Treg, and CD4+CD62L+ Treg failed to show significant differences at different stages of diabetes in comparison with pre-diabetic and/or non-diabetic NOD mice (data not shown). This evidence concerns the gene SELL and diabetes mellitus.